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Aim. To construct a recombinant eukaryotic expression plasmid containing human calcitonin (hCT) gene and express the gene
in murine ﬁbroblast NIH3T3 cells. Materials and Methods. A murine Igκ-chain leader sequence and hCT gene were synthesized
and cloned into pCDNA3.0 to form the pCDNA3.0-Igκ-hCT eukaryotic expression vector, which was transfected into NIH3T3
cells. The mRNA and protein expressions and secretion of hCT were detected. Primarily cultured osteoclasts were incubated with
the supernatant of pCDNA3.0-Igk-hCT-transfected NIH3T3 cells, and their numbers were counted and morphology observed.
Results. The expression and secretion of hCT were successfully detected in pCDNA3.0-Igk-hCT-transfected NIH3T3 cells. The
numberofosteoclastswasdecreasedandthecellsbecamecrumpledwhentheywereincubatedwiththesupernatantofpCDNA3.0-
Igk-hCT-transfected NIH3T3 cells. Conclusion. A recombinant eukaryotic expression vector containing hCT gene was successfully
constructed and expressed in NIH3T3 cells. The secreted recombinant hCT inhibited the growth and morphology of osteoclasts.
Copyright © 2009 Xiaolin Li et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Calcitonin is a 32-residue peptide hormone produced by
specialized C-parafollicular cells of the thyroid glands in
mammalsorbycellsoftheultimobranchialglandsinreptiles
and ﬁsh. The nucleotide sequence and translation of human
calcitonin are shown in Figure 1 [1, 2]. Calcitonin plays
an important role in regulating calcium and phosphorus
metabolism, decreasing blood calcium concentrations and
inhibiting bone resorption. Natural calcitonin and synthe-
sized analog are widely used in clinical practice for the
treatment of postmenopausal osteoporosis, Paget’s disease
of bone, bone pain, spinal stenosis, acute pancreatitis, and
gastric ulcer [3, 4].
Following the increase of the proportion of the elderly
people in the world, osteoporosis has become a major
threat to the public health due to its high morbidity and
mortality [5–9]. Low bone mass and deterioration of bone
microarchitecture are the major characteristics of osteoporo-
sis, which results in increased bone brittleness and thus is
associated with an increased risk for fracture. Calcitonin is
one of the eﬀective and safe agents for the treatment of
osteoporosis, along with its antalgic eﬀect [3, 4]. Calcitonins
that are used in clinical practice are mainly extracted from
the gills of salmon and pig thyroid glands [10]. However,
these heterologous products are short of resources and thus
expensive. In addition, the heterologous calcitonins are weak
antigens and antibody-related resistance occurs in 40%–70%
of patients. Moreover, side eﬀects have been observed even
through extragastrointestinal administration [11]. Dursun
et al. reported that transient or persistent nausea was
experienced in about one third of patients, with diarrhea,
vomit and local pain at the injection site being other
side eﬀects [12]. In addition, currently recommended nasal
administration of calcitonin only reaches low concentrations
in blood, but may cause squamous metaplasia in the nasal2 Journal of Biomedicine and Biotechnology
mucous membrane, which greatly restricts its long-term
application [13].
Therefore, gene engineering techniques with human
calcitonin (hCT) gene as the objective gene may provide
solutions overcoming the above drawbacks seen in clinical
practice. However, although there have been some studies on
the synthesis of calcitonin [14, 15], there is little information
in literature on its application in gene therapy. For this
purpose, we constructed a recombinant eukaryotic expres-
sion plasmid, pCDNA3.0-Igκ-hCT, which contains human
calcitonin gene and murine Igκ-chain leader sequence. The
recombinant plasmid was transferred into cells of murine
ﬁbroblastcellline,NIH3T3,andtheexpressionandsecretion
of recombinant hCT in NIH3T3 cells were observed in this
study.
2. Methods
2.1. Construction and Identiﬁcation of Recombinant pMD
18T-Ig-hCT Vector. The sequences of a murine Igκ-chain
leader sequence [16]a n dh C Tg e n e[ 1, 2] were divided into
six fragments and used as PCR primers and templates for
cDNA synthesis. The primers were as follows:
P1 :5  -CAAGCTTATGGAGACAGACACACTCCTG-
CTATGGGTACTG-3 ,
P2 :3  -TGAGGACGATACCCATGACGACGAGAC-
CCAAGGTCCAAGGTGACCACTGCGC-5 ,
P3 :5  -CAGGTTCCACTGGTGACGCGGCCCAGC-
CGGCCAGGCGCGCCGTACGGGATCCGTG-3 ,
P4 :3  -GCGCGGCATGCCCTAGGCACGCCATTA-
GACTCATGAACGTACGACCCGTGTATG-5 ,
P5 :5  -CTTGCATGCTGGGCACATACACGCAGG-
ACTTCAACAAGTTTCACACGTTCCCCCA-3 ,
P6 :3  -GTTCAAAGTGTGCAAGGGGGTTTGACG-
TTAACCCCAACCTCGTGGAATTAGATCTG-5 ,
The sequence to be synthesized was shown in Figure 1(a).
A dynamic template PCR technique was used to synthesize
Igκ-hCT (Figure 1(a))[ 17, 18]. The PCR program included
predenaturation at 95◦C for 5 minutes, 30 ampliﬁcation
cycleseachconsistingofdenaturationat94◦Cfor30seconds,
annealing at 55◦C for 60 seconds, and extension at 72◦C
for 50 seconds; followed by further extension at 72◦Cf o r5
minutes. The cloned cDNA fragments were ligated into the
pMD 18-T vector (Promega, USA) to form pMD 18-T-Igκ-
hCT. The recombinant vector pMD18T-Igκ-hCT was ampli-
ﬁed in E. coli JM109 and then extracted by a DNA puriﬁ-
cation system (Promega) according to the manufacturer’s
instructions. The designed Igκ-hCT was retrieved from the
gel. pMD18T-Igκ-hCT was digested by HindIII and XbaI
and then evaluated by 1.5% agarose gel electrophoresis. The
sequence of the recombinant Igκ-hCT eukaryotic expression
vector identiﬁed by the restriction analysis was determined
by using ﬂuorescent dideoxynuleotides on an automated
D N As e q u e n c e r( G e n ec o r eT e c h n o l o g i e sC o .L t d ,S h a n g h a i ,
China).
2.2. Construction of Recombinant pCDNA3.0-Ig-hCT Eukary-
otic Expression Vector. The procedure of construction of
the recombinant pCDNA3.0-Igκ-hCT eukaryotic expression
vector was shown in Figure 1(b). The cDNA fragment of
Igκ-hCT from pMD 18-T vector was further subcloned into
the pCDNA3.0 (Promega) to form a eukaryotic expression
vector, pCDNA3.0-Igκ-hCT. The recombinant expression
vector pCDNA3.0-Igκ-hCT was ampliﬁed in E. coli JM 109
and then extracted by a DNA puriﬁcation system (Promega).
The pCDNA3.0-Igκ-hCT retrieved from the gel was digested
by HindIII and XbaI as previously described. The digested
products were evaluated by 1.5% agarose gel electrophoresis.
2.3. Transfection of NIH3T3 Cells and Screening of Stable
Expressing Cell Lines. NIH3T3 (ATCC) cells were transfected
with pCDNA3.0-Igκ-hCT by liposome, Lipofectamine 2000
(Invitrogen, USA). Cells at 60–80% conﬂuence were trans-
fected with DNA-liposome complex at diﬀerent concentra-
tions. After 6-hours exposure, the normal culture medium,
Dulbecco’s Modiﬁed Eagle Media (DMEM),supplanted with
10% fetal bovine serum (Gibco, USA) was added into cells.
Forty eight hours later, cells were exposed to 200, 400, 600,
800, 900, and 1000μg/mL G418 (Gibco, USA), respectively,
with 3 days for each concentration [2]. After 18 days of selec-
tion, G418-resistant clones were randomly picked up, and
cultured in the medium containing 800μg/mL G418. Single
clones were transferred into and cultured in the medium
with G418 concentration being reduced to 0.5μg/mL. Thus,
hCT-transfected cells were stable selected cell lines from
single clones. NIH3T3 cells that were transfected with
pCDNA3.0 were used as controls.
2.4. Expression of hCT mRNA as Determined by RT-PCR. To
demonstrate the mRNA expression of Igκ-hCT mediated by
pCDNA3.0-Igk-hCT vector in NIH3T3 cells, totally cellular
RNA was extracted from the NIH3T3 cells by TRIzol
method. First strand cDNA was performed by an AMV
transcriptase kit (Promega) according to the manufacturer’s
instructions.Thesequencesofprimersusedforthedetection
of Igκ-hCT were 5 -TAATACGACTCACTATAGGGAGA-
3  (5 -sense) and 5 -ACTCGTATCATCCTHCCGAA-3  (3 -
antisense) with a product of 212bp. For the detection
of β-actin mRNA, we use a 5 -sense primer (5 -GGG-
AAATCGTGCGTGACAT-3 )a n da3  -antisense primer
(5 -TCAGGAGGAGCAATGATCTTG-3 ), with a product
of 385bp. PCR program was predenaturation at 95◦Cf o r5
minutes, and then 30 cycles each consisting of denaturation
at 95◦C for 50 seconds, annealing at 55◦C for 50 seconds,
extension at 72◦C for 50 seconds, and an extension at 72◦C
for 7 minutes. PCR products were electrophoresed on a 1.5%
ethidium bromide-stained agarose gel.
2.5. Detection of Expression and Secretion of
hCT Protein in NIH3T3 Cells
2.5.1. Immunohistochemistry. pCDNA3.0-Igk-hCT-transfect-
ed, nontransfect ed and pCDNA3.0-transfected NIH3T3
c e l l sw e r ec u l t u r e di n6 - w e l lp l a t e s( 1× 106/mL). One slideJournal of Biomedicine and Biotechnology 3
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Figure1:ConstructionandidentiﬁcationofrecombinantpCDNA3.0-Igκ-hCTeukaryoticexpressionvector.(a),Thesequencesthatneedto
be synthesized. The recognition sequences for HindIII, BamHIa n dXbaI restriction enzymes are shown underline. The stop codon is shown
asterisk under it. The DNA sequence of hCT is shown in boldface and italics, and the translated amino acids are under it. (b), Construction
procedures of the recombinant pCDNA3.0-Igκ-hCT eukaryotic expression vector. (c), Electrophoresis of recombinant plasmid pCDNA3.0-
Igκ-hCT digested with HindIII and XbaI.
was put in each well of six-well plates for 24 hours to grow
NIH3T3 cells. Then, immunohistochemistry was performed
on ethyl alcohol/acetone-ﬁxed slides by immunohistological
kit for hCT (Zhongshan Golden Bridge, Beijing, China).
2.5.2. Western Blotting. Supernatant of cultured pCDNA3.0-
Igk-hCT-transfectedNIH3T3cellsweresubjectedtoWestern
blotting after 10 fold condensation by lyophilization, with
pCDNA3.0-transfected NIH3T3 cell culture enriched super-
natant being used a control. After electrophoresis and trans-
fer of samples onto nitrocellulose membrane (Amersham
Biosciences Inc. Piscataway, USA), the blots were probed
with the following antibodies: rabbit antihCT (Chemicon
International Inc.,Temecula, USA) and goat antirabbit IgG-
HRP (Chemicon International Inc.). Films were developed
by the chemiluminescence method.4 Journal of Biomedicine and Biotechnology
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Figure 2: Expression of hCT mRNA and protein in NIH3T3 cells. (a). Igκ-hCT mRNA expression in NIH3T3 cells by RT-PCR. Lane
M :m a r k e r ;L a n e1 :R T - P C Rp r o d u c t sf r o mp C D N A 3 . 0 - I g κ-hCT-transfected NIH3T3 cells; Lane 2: RT-PCR product from pCDNA3.0-
transfected cells (negative control); Lane 3: RT-PCR product from nontransfected cells. (b), Immunohistological staining of hCT protein
in pCDNA3.0-Igκ-hCT-transfected (b1), nontransfected (b2) and pCDNA3.0-transfected NIH3T3 cells (b3). All magniﬁcation ×200. (c).
Western blotting showing hCT protein was detected in pCDNA3.0-Igk-hCT-transfected cells (lanes 1–4), but not in pcDNA3.0 transfected
cells (lane 5).
2.5.3. Radioimmunoassay. pCDNA3.0-Igk-hCT-transfected,
nontransfected and pCDNA3.0-transfected NIH3T3 cells
were cultured in 6-well plates (1×106 cells/mL). The culture
medium was replaced with a serum-free medium 24 hours
later. After the cells were cultured for 24 hours, secretion of
hCT in the supernatant was measured with a commercial
hCT detection kit (Cehmclin, Beijing, China) by using the
radioimmuniassay method.
2.6. In Vitro Eﬀe c to fE x p r e s s e dh C To nO s t e o c l a s t s . pCDNA
3.0-Igk-hCT-transfected, nontransfected and pCDNA3.0-
transfected NIH3T3 cells were cultured in 6-well plates (1 ×
106/mL) for 24 hours.Then, primarily isolated osteoclasts
were settled onto the 6-well plates and cocultured with above
NIH3T3cells,respectively,on15mmplasticcoverslipswhich
were placed on a metallic bracket in plates, and incubated
for 7 days at 37◦C. As a positive control, salmon CT (sCT,
Novartis, Basel, Switzerland) was added, at concentration
of 1ng/mL, into the coculture of nontransfected NIH3T3
cells and osteoclasts. To determine the identity of osteoclasts,
cells were ﬁxed and stained by using a tartrate-reisitant acid
phosphatase (TRAP) stain kit (Sigma, USA) according to
the manufacturer’s protocol on day 7 of culture. TRAP-
positive multinucleated cells with more than three nuclei
were considered to be osteoclasts (Figure 3)[ 19]. Finally, the
osteoclastswereobservedunderaconvertedmicroscope,and
their numbers were counted and morphology observed.
2.7. Statistical Analysis. Results were expressed as means ±
standard deviation (SD). Database was set up with SPSS 10.0
software package (SPSS Inc, Chicago, IL) for analysis. The
signiﬁcance of diﬀerences was determined by ANOVA and
Bonferroni’s modiﬁcation of Student’s t-test. A diﬀerence
with a P value of less than.05 was considered statistically
signiﬁcant.
3. Results
3.1.EvaluationandSequenceAnalysisofRecombinantPlasmid
pMD 18T-Ig-hCT. The PCR product of pMD18T-Igκ-hCTJournal of Biomedicine and Biotechnology 5
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Figure 3:Primarilyisolatedosteoclastscoculturedwithnontransfected(a)andpCDNA3.0-transfected(b),pCDNA3.0-Igκ-hCT-transfected
(c) NIH3T3 cells and nontransfected NIH3T3 cells plus sCT (d). TRAP staining shows that primarily isolated osteoclasts are multinucleate
and spreading cells, which become crumpled when cocultured with pCDNA3.0-Igκ-hCT-transfected.
Table 1: The number of TRAP-positive multinucleate cells when
osteoclasts were cocultured in vitro with pCDNA3.0-Ig-hCT-
transfected, and nontransfected, pCDNA3.0-transfected NIH3T3
cells, or nontransfected NIH3T3 cells plus sCT.
Group
Number of TRAP-positive
multinucleate cells (means ±
SD)
Nontransfected group 18.3 ±3.2
pCDNA3.0-transfected
group 16.9 ±2.7
pCDNA3.0-Igκ-hCT-
transfected
group
12.7 ±1.9∗
Nontransfected group plus
sCT 9.5 ±2.4∗∗
∗ P<. 01, compared with nontransfected group and pCDNA3.0-transfected
group. ∗∗P<. 01, compared with pCDNA3.0-transfected group.
had the same length with designed Igκ-hCT gene. Igκ-hCT-
cDNA was successfully inserted into pMD18T as shown
by HindIII and XbaI digestion and electrophoresis (data
not shown). The pMD18T-Igκ-hCT identiﬁed by restriction
analysis was sequenced. It was demonstrated that the stop
codon and endonuclease sites of Igκ-hCT was successfully
cloned into pMD18-T (data not shown).
3.2. Evaluation of pCDNA3.0-Igk-hCT. The Igκ-hCT cDNA
was successfully ligated into pCDNA3.0 by HindIII and XbaI
digestion and electrophoresis (Figure 1(c)).
3.3. Expression of hCT mRNA and Protein in NIH3T3 Cells.
The 210bp fragment corresponding to the Igκ-hCT cDNA
ampliﬁedbyRT-PCRwaspresentonlyfrompCDNA3.0-Igk-
hCT-transfected NIH3T3 cells, but not from nontransfected
or pCDNA3.0-transfected cells (Figure 2(a)).
Moreover, immunocytochemistry staining showed that
expression of hCT protein was detected in pCDNA3.0-
Igk-hCT-transfected NIH3T3 cells (Figure 2(b)1), but not
in pCDNA3.0-transfected or nontransfected cells (Figures
2(b)2a n d2(b)3).
3.4. Expression and Secretion of hCT Protein in NIH3T3 Cell
Culture Supernatants. Western blotting showed tha hCT was
positively stained in pCDNA3.0-Igk-hCT-transfected cells,
but not in pCDNA3.0-transfected or nontransfected cell
(Figure 2(c)).
In addition, radioimmunoassay displayed signiﬁcantly
higher secretion of hCT protein in the culture supernatant
(46 ± 7.29ng/mL) of pCDNA3.0-Igk-hCT-transfected
NIH3T3 cells than those of nontransfected cells (5.2 ±
2.36ng/mL) and pCDNA3.0-transfected cells (4.8 ±
4.31ng/mL) (both P<. 05).6 Journal of Biomedicine and Biotechnology
3.5. Eﬀect of Expressed and Secreted hCT on Osteoclasts.
TRAP staining showed that primarily isolated osteoclasts
cocultured with nontransfected and pCDNA3.0-transfected
cells were multinucleate and spreading under a converted
microscope (Figures 3(a) and 3(b)). However, it was
observed that osteoclasts became crumpled when cocultured
with pCDNA3.0-Igκ-hCT-transfected NIH3T3 cells and
nontransfected NIH3T3 cells plus sCT group. (Figures 3(c)
and 3(d)). The number of TRAP-positive multicleate cells
was signiﬁcantly fewer when the primarily isolated osteo-
clasts were cocultured with pCDNA3.0-Igκ-hCT-transfected
NIH3T3 cells or with nontransfected NIH3T3 cells plus sCT,
than with nontransfected or pCDNA3.0-transfected cells
(Table 1, P<. 01).
4. Discussion
Osteoporosis is characterized with low bone mass and
deterioration of bone microarchitecture which can cause
decreased bone strength and an increased risk for fracture
[5–9]. Calcitonin is one of the most eﬀective reagents for
osteoporosis with antalgic activities [3, 4]. It is believed that
sCT can inhibit bone resorption, reduce bone mass loss and
relieve bone pain [20, 21]. But oral or nasal administration
of calcitonin can cause many side eﬀects in osteoporosis
patients[12,13].Otherwise,long-termapplicationofanimal
calcitonins leads to a sharp activity decrease in clinical
use of osteoporosis due to the accumulation of antibodies
against these heterologous calcitonins [11]. However, it is
very diﬃcult to extract bioactive calcitonin from humans.
Genetic engineering strategies provide new methods for
production of hCT. Therefore, gene therapy with calcitonin
as an objective gene may represent an optimal resolution to
overcome the above problems.
hCT cannot be secreted after synthesized in the cyto-
plasm because the nucleotide sequence of hCT1-32 lacks of
a signal peptide, which greatly limits its application in gene
therapy [22]. In the present study, we added a murine Igκ-
chain leader sequence to hCT. Thus, hCT can be secreted
into the culture supernatant after it is synthesized in the
cytoplasm. At the same time, the signal peptide is cleaved to
avoid inﬂuencing the activities of hCT [16]. In this study, the
synthetic coding sequences for Igκ-hCT is created by ligation
of six oligonucleotides. There are 19 or 20 complementary
bases between P1 and P2,P 2 and P3,P 3 and P4,P 4 and P5,
andP5 andP6.IntheﬁrststageofPCR,P1 andP2,P 3 andP4,
and P5 and P6 were used as primers and templates to amplify
P1-2 ,P 3-4 and P5-6. In the second stage, P1-2,P 3-4 and P5-6
wereusedasprimersandtemplatestoamplifyP1–4 andP3–6.
Then, they were used as primers and templates to amplify
the target sequence. The integrated target sequence was
synthesized after consecutive PCRs. The sequence analysis
and electrophoresis of pCDNA3.0-Igκ-hCT after digestion
with HindIII and XbaI demonstrated that the objective gene
Igκ-hCT was successfully cloned and ligated into the eukary-
otic expression vector. The 210bp fragment corresponding
to the Igκ-hCT cDNA was ampliﬁed by RT-PCR, and
was expressed only from pCDNA3.0-Igk-hCT-transfected
NIH3T3 cells. The expression and secretion of hCT were also
detected in pCDNA3.0-Igκ-hCT-transfected NIH3T3 cells
by the immunohistological method, Western blotting and
the radioimmunoassay method. These observations suggest
that the target fragment was successfully integrated into
the genome of infected NIH3T3 cells, which was expressed
successfully.
It has been shown that calcitonin inhibits bone resorp-
tion and induces osteoclast apoptosis by binding to calci-
tonin receptors on osteoclasts [23]. The present study con-
ﬁrmed these ﬁndings. We observed that primarily isolated
osteoclasts cocultured with the supernatant of pCDNA3.0-
Igk-hCT-transfected NIH3T3 cells became crumpled and
their number was decreased compared with those cocultured
in nontransfected and pCDNA3.0-transfected NIH3T3 cells,
which suggests its profound bioactivities such as inhibition
of the growth and alteration of morphology of osteoclasts.
Many in vivo active peptides are posttranslationally
amidated at the C terminus, which is of great importance
to their activities and stability. However, we did not make
any posttranslational modiﬁcations to the recombinant
hCT. Eukaryotes can be used to make some modiﬁcations
to products, which make it possible to directly produce
amidated calcitonin. In our future research, we will aim
to couple express a rat amidating enzyme and hCT-Gly in
NIH3T3 cells, to obtain amidated bioactive hCT [11].
Microencapsulation is a technique that encapsules an
implant into a biocompatible selective membrane made
from polymers, which can insulate the implant and the
immune system of the recipient, but allow small molecules,
electrolytes, oxygen, and metabolites to get through the
membrane [24]. Indeed, microencapsulated transplantation
of cells and tissues has been demonstrated to be eﬀective
in the treatment of many diseases [25]. We propose that
cell lines secreting hCT encapsulated by alginate-polylysine-
alginate membranes microcapsules and transplanted would
constantly secret bioactive hCT for a long perioid of time in
vivo, and thus represent a new strategy for the treatment of
osteoporosis.
In conclusion, we successfully constructed the recom-
binant eukaryotic expression plasmid containing Igκ-hCT
gene.ThehCTgenewaseﬀectivelyexpressedinNIH3T3cells
and secreted into the culture supernatant with the help of
the murine Igκ-chain leader sequence. The expressed and
secreted hCT inhibited growth and altered morphology of
primarily isolated osteoclasts. This study provides exper-
imental data for potential gene therapeutic usage of the
recombinant hCT for osteoporosis.
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